$101,872.63 research Payment -- Gilead Sciences to Dr. Rachel Parker

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Gilead Sciences made a $101.9K research payment to Rachel Parker, a Infectious Disease specialist in Macon, GA. The payment was associated with Wegovy. Gilead Sciences paid $101,872.63 to Dr. Rachel Parker for research related to Wegovy. The payment was made on July 17, 2025, and is categorized as research. Dr. Parker's specialty is Infectious Disease, and the payment was made in Macon, GA.

Patient Guidance: What This Payment Means for You

This payment was for research purposes and may contribute to understanding new treatments or therapies. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for research in Infectious Disease can vary widely depending on the scope and duration of the study; this amount is significant but context-dependent.

Regulatory Context: Sunshine Act Requirements

This payment falls under the Sunshine Act's reporting requirements for payments made by manufacturers to physicians.

Related Topics

This payment is related to the following healthcare transparency topics:

• gilead-sciences
• research-payment
• infectious-disease
• wegovy
• pharma-transparency
• open-payments

Understanding research Payments

Research payments fund clinical trials, research studies, and investigator-initiated research conducted by physicians. These payments are often the largest category and represent a critical part of the drug development process. Research funding is generally considered the most legitimate form of pharmaceutical payment, though potential conflicts of interest can still arise when researchers have financial relationships with the companies whose products they study.

Frequently Asked Questions About This Payment

What was this $101.9K payment for?

This was a research payment of $101.9K from Gilead Sciences to Rachel Parker, categorized as "Research". It was associated with Wegovy. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Rachel Parker accept pharmaceutical money?

Yes, Rachel Parker received this $101.9K payment from Gilead Sciences. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Rachel Parker's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this research payment?

A research payment of $101.9K typically funds clinical studies and is considered standard academic activity. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Infectious Disease?

To compare this payment against Infectious Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Infectious Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Rachel Parker's relationship with Gilead Sciences?

The payment amount is substantial, exceeding $100,000. This $101.9K research payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Infectious Disease?

The payment is specifically for research activities.

What should patients do after learning about this payment?

This payment was for research purposes and may contribute to understanding new treatments or therapies.

What else should I know about this research payment?

The drug associated with the payment is Wegovy, though the specialty is Infectious Disease.

Related Reports

• View Dr. Rachel Parker's full payment report
• Gilead Sciences full spending report
• Browse all Infectious Disease payments
• Browse all payments in Georgia
• Search for other payments